<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03015727</url>
  </required_header>
  <id_info>
    <org_study_id>ZhejiangCH 01536224</org_study_id>
    <nct_id>NCT03015727</nct_id>
  </id_info>
  <brief_title>Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma</brief_title>
  <acronym>IRCNPC</acronym>
  <official_title>Induction Chemotherapy With Docetaxel and Cisplatin Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhejiang Provincial Peopleâ€™s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Central Hospital of Lishui City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jinhua Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Wenzhou Medical Univeristy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ningbo Medical Center Lihuili Eastern Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>People's Hospital of Quzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators aim to compare the progression-free survival (PFS) and side
      effects of radiotherapy (RT) and concurrent chemoradiotherapy (CCRT) in locoregionally
      advanced nasopharyngeal carcinoma (NPC) patients with a satisfactory tumor response (complete
      response or partial response) after neoadjuvant chemotherapy (NACT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the investigators aim to compare the survival outcomes and side effects of
      radiotherapy (RT) and concurrent chemoradiotherapy (CCRT) in locoregionally advanced
      nasopharyngeal carcinoma (NPC) patients with a satisfactory tumor response (complete response
      or partial response) after neoadjuvant chemotherapy (NACT) with Docetaxel and Cisplatin
      treated using intensity-modulated radiotherapy (IMRT) or tomotherapy (TOMO).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progress Free Survival (PFS)</measure>
    <time_frame>3 years after the inception assignment</time_frame>
    <description>PFS means assignment to the date of any local or distant progress of the disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>3 years and 5 years after the inception of the assignment</time_frame>
    <description>The overall survival denote to assignment to date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 100 days and every 3 months thereafter for 5 years</time_frame>
    <description>Observe and record the toxicity profile (including but not limit to mucositis, liver and kidney function, et al.) according NCI-CTCAE (3rd edition) during the neoadjuvant chemotherapy, chemoradiation and follow-up.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Locally Advanced Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>IC+RT group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 cycles of TP neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2 and cisplatin 75mg/m2. And then radiation using IMRT/TOMO without concurrent chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IC+CCRT group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 cycles of TP neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2 and cisplatin 75mg/m2.And then chemoradiation using IMRT/TOMO with 2 cycles of cisplatin concurrent chemotherapy at 100mg/m2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>3 cycles of DOC neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2.</description>
    <arm_group_label>IC+RT group</arm_group_label>
    <arm_group_label>IC+CCRT group</arm_group_label>
    <other_name>DOC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>3 cycles of DDP neoadjuvant chemotherapy at day1,22 and 43 with cisplatin 75mg/m2.</description>
    <arm_group_label>IC+RT group</arm_group_label>
    <arm_group_label>IC+CCRT group</arm_group_label>
    <other_name>DDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT/TOMO</intervention_name>
    <description>intensity modulated radiation therapy or tomotherapy</description>
    <arm_group_label>IC+RT group</arm_group_label>
    <arm_group_label>IC+CCRT group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>2 cycles of cisplatin concurrent chemotherapy at day 64 and 85 with cisplatin 100mg/m2.</description>
    <arm_group_label>IC+CCRT group</arm_group_label>
    <other_name>concurrent chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with newly histologically confirmed non-keratinizing carcinoma.

          2. Tumor staged as N2-3 or T3-4 (according to the 7th AJCC staging system)

          3. No evidence of distant metastasis (M0)

          4. Performance status: KPS&gt;70

          5. With normal liver function test (ALT, AST &lt;1.5ULN)

          6. Renal: creatinine clearance &gt;60ml/min

          7. Without hematopathy,marrow: WBC &gt;4*109/L, HGB&gt;80G/L, and PLT&gt;100*109/L.

          8. With controlled blood glucose for diabetes patients

          9. Written informed consent

         10. satisfactory tumor response (complete response or partial response) after neoadjuvant
             chemotherapy (NACT)

        Exclusion Criteria:

          1. WHO type I squamous cell carcinoma or adenocarcinoma

          2. Age &gt;65 or &lt;18

          3. With a history of renal disease

          4. Prior malignancy (except adequately treated carcinoma in-situ of the cervix or
             basal/squamous cell carcinoma of the skin)

          5. Previous chemotherapy or radiotherapy (except non-melanomatous skin cancers outside
             the intended RT treatment volume)

          6. Patient is pregnant or lactating

          7. Peripheral neuropathy

          8. Emotional disturbance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaozhong Chen</last_name>
    <role>Study Chair</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaozhong Chen</last_name>
    <email>cxzfyun@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xiaozhong Chen</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaozhong Chen, MD</last_name>
      <phone>+86-571-88128202</phone>
      <email>cxzfyun@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 24, 2016</study_first_submitted>
  <study_first_submitted_qc>January 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2017</study_first_posted>
  <last_update_submitted>January 9, 2017</last_update_submitted>
  <last_update_submitted_qc>January 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nasopharyngeal carcinoma</keyword>
  <keyword>Induction chemotherapy</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>chemoradiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

